A nanomedicine research group led by a University of Toronto chemist has received a $5-million grant from the Natural Sciences and Engineering Research Council of Canada (NSERC), giving them the green light to develop faster ways of detecting leukemia and lung cancer cells.
Held in Edmonton, AB, Canada, and co-sponsored by TAPPI and the Alberta Ingenuity Fund, the conference revealed developments for revolutionizing paper and wood products, as well as capturing sustainability-focused markets with bionanocomposites and capitalizing on wood-derived nanocrystalline cellulose and nanofibrillar cellulose.
Researchers have developed technology to perform more than a thousand chemical reactions at once on a stamp-size, PC-controlled microchip, which could accelerate the identification of potential drug candidates for treating diseases such as cancer.
Biomedical researchers at the University of Arkansas in Fayetteville and the University of Arkansas for Medical Sciences (UAMS) in Little Rock have developed a special contrast-imaging agent made of gold-coated carbon nanotubes that is capable of molecular mapping of lymphatic endothelial cells and detecting cancer metastasis in sentinel lymph nodes.
Scientists from Argonne National Laboratory and the University of Chicago Medical Center's Brain Tumor Center have developed a way to target brain cancer cells using inorganic titanium dioxide nanoparticles bonded to antibodies.
Small pieces of nucleic acid known as short interfering RNAs, or siRNAs, can turn off the production of specific proteins, a property that makes them one of the more promising new classes of anticancer drugs in development.